Atherosclerosis development in SLE patients is not determined by monocytes ability to bind/endocytose Ox-LDL

Autoimmunity

Volumn 44, Issue 3, 2011, Pages 201-210

  Yassin, Lina M ^a   Londoño, Julián ^a   Montoya, Guillermo ^a   De Sanctis, Juan B ^b   Rojas, Mauricio ^a   Ramírez, Luis A ^a   García, Luis F ^a   Vásquez, Gloria ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Atherosclerosis; endocytosis; OxLDL; scavenger receptors; SLE

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CAPTOPRIL; CD163 ANTIGEN; CD36 ANTIGEN; CHLOROQUINE; CYCLOPHOSPHAMIDE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXIDIZED LOW DENSITY LIPOPROTEIN; PREDNISOLONE; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD36; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; ENDOCYTOSIS; HUMANS; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MONOCYTES; OXIDATION-REDUCTION; PROTEIN BINDING; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 79953125414     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.530626     Document Type: Article

References (51)

1. Hansson GK, Robertson AK, Soderberg-Naucler C Inflam-mation and atherosclerosis. Annu Rev Pathol 2006;1:297-329.
2. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75. (Pubitemid 46670686)
3. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogen-esis. Science 1991;251:788-791.
4. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010;134:5-24.
5. Tulenko TN, Sumner AE. The physiology of lipoproteins. J Nucl Cardiol 2002;9:638-649. (Pubitemid 36050211)
6. Peiser L, Gordon S. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect 2001;3:149-159. (Pubitemid 32209332)
7. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264-8268.
8. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-261. (Pubitemid 13030685)
9. Sherer Y, Zinger H, Shoenfeld Y Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010;43:98-102.
10. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythemato-sus. N Engl J Med 2003;349:2399-2406. (Pubitemid 37542988)
11. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54: 2550-2557. (Pubitemid 44205016)
12. Jonsson H, Nived O, Sturfelt G Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-150. (Pubitemid 19132411)
13. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:408-415. (Pubitemid 27084212)
14. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato K, Castellot JJ Jr, Walsh K. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004;199:1121-1131. (Pubitemid 38619908)
15. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-2337. (Pubitemid 32977500)
16. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproli-ferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-976. (Pubitemid 24106378)
17. Yassin LM, Rojas M, Ramirez LA, Garcia LF, Vasquez G Monocyte activation by apoptotic cells removal in systemic lupus erythematosus patients. Cell Immunol 2010;266: 52-60.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277. (Pubitemid 13221242)
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640.
20. Wilson T, March H, Ban WJ, Hou Y, Adler S, Meyers CY, Winters TA, Maher MA. Antioxidant effects of phyto-and synthetic-estrogens on cupric ion-induced oxidation of human low-density lipoproteins in vitro. Life Sci 2002;70: 2287-2297. (Pubitemid 34251298)
21. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75. (Pubitemid 19109796)
22. Bird RP, Draper HH. Comparative studies on different methods of malonaldehyde determination. Methods Enzymol 1984;105:299-305. (Pubitemid 14165390)
23. De Sanctis JB, Blanca I, Bianco NE. Expression of different lipoprotein receptors in natural killer cells and their effect on natural killer proliferative and cytotoxic activity. Immunology 1995;86:399-407.
24. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis 1981;1:177-185. (Pubitemid 11024320)
25. Hed J, Hallden G, Johansson SG, Larsson P. The use of fluorescence quenching in flow cytofluorometry to measure the attachment and ingestion phases in phagocytosis in peripheral blood without prior cell separation. J Immunol Methods 1987;101:119-125. (Pubitemid 17097906)
26. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. (Pubitemid 29024679)
27. Tomasik A, Jachec W, Skrzep-Poloczek B, Widera-Romuk E, Wodniecki J, Wojciechowska C Circulating electronegatively charged low-density lipoprotein in patients with angiographi-cally documented coronary artery disease. Scand J Clin Lab Invest 2003;63:259-265.
28. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005;257:485-495. (Pubitemid 40776508)
29. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-1847. (Pubitemid 28213628)
30. Dawber TR, Kannel WB, Revotskie N, Stokes J III, Kagan A, Gordon T Some factors associated with the development of coronary heart disease: Six years' follow-up experience in the Framingham study. Am J Public Health Nations Health 1959; 49:1349-1356.
31. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and 'lupus dyslipoproteinemia'. Autoimmun Rev 2008;7:246-250.
32. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008;199:3-11.
33. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60: 221-225.
34. Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Sawamura T, Gioffre WR, Auteri A, Puccetti L. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholester-olemic subjects. Clin Appl Thromb Hemost 2005;11: 417-428. (Pubitemid 41546768)
35. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro-and antiinflammatory stimuli. J Leukoc Biol 2000;67: 97-103. (Pubitemid 30046823)
36. Ballou SP, Lozanski FB, Hodder S, Rzewnicki DL, Mion LC, Sipe JD, Ford AB, Kushner I. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 1996;25:224-230. (Pubitemid 26152041)
37. Yung RL, Julius A. Epigenetics, aging, and autoimmunity Autoimmunity 2008;41:329-335.
38. Goldstein JI, Goldstein KA, Wardwell K, Fahrner SL, Goonan KE, Cheney MD, Yeager MP, Guyre PM. Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 2003;170: 325-332. (Pubitemid 37377806)
39. Teupser D, Stein O, Burkhardt R, Nebendahl K, Stein Y Thiery J. Scavenger receptor activity is increased in macrophages from rabbits with low atherosclerotic response: Studies in normocholesterolemic high and low atherosclerotic response rabbits. Arterioscler Thromb Vasc Biol 1999;19: 1299-1305. (Pubitemid 29227651)
40. Jalkanen J, Leppanen P, Narvanen O, Greaves DR, Ya-Herttuala S. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. Atherosclerosis 2003;169:95-103. (Pubitemid 36830927)
41. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997;386:292-296. (Pubitemid 27142516)
42. Sakaguchi H, Takeya M, Suzuki H, Hakamata H, Kodama T, Horiuchi S, Gordon S, van der Laan LJ, Kraal G, Ishibashi S, Kitamura N, Takahashi K Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest 1998;78:423-434. (Pubitemid 28207855)
43. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against athero-sclerotic lesion development in mice. J Clin Invest 2000;105: 1049-1056. (Pubitemid 30217689)
44. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipi-demic mice. J Clin Invest 2005;115:2192-2201. (Pubitemid 41134161)
45. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924. (Pubitemid 19101597)
46. Naito M, Suzuki H, Mori T, Matsumoto A, Kodama T, Takahashi K Coexpression of type I and type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. Am J Pathol 1992;141:591-599.
47. Rivas L, Zabaleta M, Toro F, Bianco NE, De Sanctis JB. Decreased transcription, expression and function of low-density lipoprotein receptor in leukocytes from patients with systemic lupus erythematosus. Autoimmunity 2009;42: 266-268.
48. Hsu HY, Chiu SL, Wen MH, Chen KY, Hua KF. Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways. J Biol Chem 2001;276:28719-28730.
49. Janabi M, Yamashita S, Hirano K, Sakai N, Hiraoka H, Matsumoto K, Zhang Z, Nozaki S, Matsuzawa Y Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defec-tive in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000;20: 1953-1960. (Pubitemid 30648813)
50. Martin-Fuentes P, Civeira F, Recalde D, Garcia-Otin AL, Jarauta E, Marzo I, Cenarro A. Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J Immunol 2007;179: 3242-3248.
51. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003;83:1069-1112. (Pubitemid 37222268)